- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05545839
Transition to Adulthood Through Coaching and Empowerment in Rheumatology (TRACER)
March 16, 2023 updated by: Michelle Batthish, McMaster University
TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, A Feasibility Study
TRACER is a study aiming to investigate the feasibility of transition coaching sessions for patients moving from paediatric to adult rheumatology care.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
TRACER is a feasibility study investigating transition coaching for patients with rheumatic disease transferring from paediatric to adult rheumatology care.
This is a vulnerable time in the patients' care and life as they are assuming more responsibility for their health and undergoing significant life transitions.
There is risk for increased morbidity and mortality around this time if the patient are not well supported and if they do not stay engaged with care.
This intervention aim to provide self-efficacy, self-management, coping skills and support to patients making the transition.
This study aims to assess the feasibility of conducting a multi-centre randomized trial.
Study Type
Interventional
Enrollment (Anticipated)
133
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michelle Batthish, MD
- Phone Number: 75382 1-905-521-2100
- Email: batthim@mcmaster.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Recruiting
- McMaster Children's Hospital
-
Contact:
- Michelle Batthish, MD
- Phone Number: 75382 1-905-521-2100
- Email: batthim@mcmaster.ca
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- Children's Hospital at London Health Sciences Centre
-
Contact:
- Roberta Berard, MD
- Phone Number: 58266 1-519-685-8500
- Email: roberta.berard@lhsc.on.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient with pediatic-onset rheumatic disease
- At their last paediatric rheumatology appointment prior to transferring to adult rheumatology care
- Able to communicate in English
- Have a phone or device capable of participating in video conference
- Available over the next 8 months
Exclusion Criteria:
- Cognitive impairment preventing participation in individualized education sessions (as determined by medical staff)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard care - control
Standard of care, appointments with adult rheumatology
|
|
Experimental: Transition coaching - experimental
Participants will receive 8 transition coaching sessions (1/month) in addition to standard care
|
Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Consent rate
Time Frame: 19 month recruitment period
|
% of patients approached who consent to the study
|
19 month recruitment period
|
Enrolment from non-primary site
Time Frame: 19 month
|
% of patients enrolled from non-primary site
|
19 month
|
Virtual session attendance
Time Frame: 3 year study period
|
% of transition coaching sessions attended
|
3 year study period
|
Outcome measure completion
Time Frame: 3 year study period
|
% of outcome assessments completed at 8 months (end of transition coach invention)
|
3 year study period
|
Missing data
Time Frame: 3 year study period
|
% of missing data
|
3 year study period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Outcomes Measurement Information System (PROMIS) questionnaire
Time Frame: 3 year study period
|
Descriptive statistics of PROMIS questionnaire (person-centered measures to assess how people feel and function) results at baseline, 8 months and 11 months, between the two groups.
|
3 year study period
|
Physician Global Assessment (PGA)
Time Frame: 3 year study period
|
Descriptive statistics of physical global assessment at baseline and at subsequent follow-up, between the two groups.
Physician Global Assessment refers to MD assessment of disease activity and is rated between 0 (no disease activity) and 10 (most active disease).
|
3 year study period
|
Active joint count
Time Frame: 3 year study period
|
Descriptive statistics of active joint count (joints with evidence of active inflammation - including swelling, tenderness, loss of ROM) at baseline and at subsequent follow-up, between the two groups
|
3 year study period
|
Global function/quality of life
Time Frame: 3 year study period
|
Descriptive statistics of PedsQL (Paediatric Quality of Life Inventory) 4.0 Generic Core Scales Young Adult Version questionnaire results at baseline, 8 months and 11 months, between the two groups.
|
3 year study period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michelle Batthish, MD, McMaster University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 17, 2022
Primary Completion (Anticipated)
April 1, 2025
Study Completion (Anticipated)
April 1, 2025
Study Registration Dates
First Submitted
September 13, 2022
First Submitted That Met QC Criteria
September 16, 2022
First Posted (Actual)
September 19, 2022
Study Record Updates
Last Update Posted (Actual)
March 20, 2023
Last Update Submitted That Met QC Criteria
March 16, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Spondylitis
- Psoriasis
- Polymyositis
- Myositis
- Arthritis
- Arthritis, Psoriatic
- Dermatomyositis
- Autoimmune Diseases
- Arthritis, Juvenile
Other Study ID Numbers
- 14499
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiRecruitingHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on Transition coaching
-
Washington University School of MedicineRecruitingMultiple MyelomaUnited States
-
Christopher BarwaczCompletedEsthetics, Dental | Dental Implant, Single-ToothUnited States
-
BaycrestOntario Ministry of Health and Long Term CareTerminatedDementia | BPSDCanada
-
University of KansasCompletedType 1 DiabetesUnited States
-
Karolinska InstitutetForteRecruitingStroke | Transient Ischemic AttackSweden
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH); Aurum InstituteCompletedHiv | Adherence, PatientSouth Africa
-
McMaster UniversityRecruitingInflammatory Bowel Diseases | Juvenile Idiopathic ArthritisCanada
-
Johns Hopkins UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedFrail Elderly | Transitional Care | Home Health CareUnited States
-
McMaster UniversityCompletedEating Disorders | Eating Disorders in AdolescenceCanada
-
University of Southern CaliforniaThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType 1 Diabetes MellitusUnited States